Publications
*co-first author; #co-corresponding author
Miao, B*; Hu, Z*; Mezzadra, R*; Hoeijmakers, L*; Fauster, A; Du, S; Yang, Z; Sator-Schmitt, M; Engel, H; Li, X; Broderick, C; Jin, G; Gomez-Eerland, R; Rozeman, L; Lei, X; Matsuo, H; Yang, C; Hofland, I; Peters, D; Broeks, A; Laport, E; Fitz, A; Zhao, X; Mahmoud, M. A. A; Ma, X; Sander, S; Liu, H. K; Cui, G; Gan, Y; Wu, W; Xiao, Y; Heck, A. J. R; Guan, W; Lowe, S. W; Horlings, H. M; Wang, C; Brummelkamp, T. R; Blank, C. U#; Schumacher, T. N. M.# & Sun, C#. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. Cancer Cell 41, 1-12, doi:10.1016/j.ccell.2023.08.008 (2023).
Lei, X., Khatri, I., de Wit, T., de Rink, I., Nieuwland, M., Kerkhoven, R., van Eenennaam, H., Sun, C., Garg, A. D., Borst, J. & Xiao, Y. CD4(+) helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment. Nat Commun 14, 217, doi:10.1038/s41467-022-35615-5 (2023)
Li, Y.*, Yang, C.*, Liu, Z.*, Du, S.*, Can, S., Zhang, H., Zhang, L., Huang, X., Xiao, Z., Li, X., Fang, J., Qin, W., Sun, C.#, Wang, C.#, Chen, J.# & Chen, H.# Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy. Molecular Cancer 21, 2, doi:10.1186/s12943-021-01462-z (2022).
Jin, H., Shi, Y., Lv, Y., Yuan, S., Ramirez, C. F. A., Lieftink, C., Wang, L., Wang, S., Wang, C., Dias, M. H., Jochems, F., Yang, Y., Bosma, A., Hijmans, E. M., de Groot, M. H. P., Vegna, S., Cui, D., Zhou, Y., Ling, J., Wang, H., Guo, Y., Zheng, X., Isima, N., Wu, H., Sun, C., Beijersbergen, R. L., Akkari, L., Zhou, W., Zhai, B., Qin, W. & Bernards, R. EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 730-734, doi:10.1038/s41586-021-03741-7 (2021).
Sun, C.*, Mezzadra, R.* & Schumacher, T. N.* Regulation and Function of the PD-L1 Checkpoint. Immunity 48, 434-452, doi:10.1016/j.immuni.2018.03.014 (2018).
Mezzadra, R.*, Sun, C.*, Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., Broeks, A., Horlings, H. M., Wessels, L. F. A., Blank, C. U., Xiao, Y., Heck, A. J. R., Borst, J., Brummelkamp, T. R. & Schumacher, T. N. M. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106-110, doi:10.1038/nature23669 (2017)
Sun, C.*, Wang, L.*, Huang, S.*, Heynen, G. J., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. & Bernards, R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122, doi:10.1038/nature13121 (2014)
Papadakis, A. I.*, Sun, C.*, Knijnenburg, T. A., Xue, Y., Grernrum, W., Holzel, M., Nijkamp, W., Wessels, L. F., Beijersbergen, R. L., Bernards, R. & Huang, S. SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Res 25, 445-458, doi:10.1038/cr.2015.16 (2015).
Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., Schlicker, A., Wessels, L. F., Smit, E. F., Thunnissen, E., Halonen, P., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., Bardelli, A., Trusolino, L. & Bernards, R. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep 7, 86-93, doi:10.1016/j.celrep.2014.02.045 (2014).
Lamba, S.*, Russo, M.*, Sun, C.*, Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F. & Bardelli, A. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep 8, 1475-1483, doi:10.1016/j.celrep.2014.07.033 (2014).
Sun, C. & Bernards, R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci 39, 465-474, doi:10.1016/j.tibs.2014.08.010 (2014).
Prahallad, A.*, Sun, C.*, Huang, S.*, Di Nicolantonio, F.*, Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A. & Bernards, R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103, doi:10.1038/nature10868 (2012)
Huang, S., Holzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., Groenendijk, F. H., Mittempergher, L., Nijkamp, W., Neefjes, J., Salazar, R., Ten Dijke, P., Uramoto, H., Tanaka, F., Beijersbergen, R. L., Wessels, L. F. & Bernards, R. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 151, 937-950, doi:10.1016/j.cell.2012.10.035 (2012).
Carette, J. E., Guimaraes, C. P., Wuethrich, I., Blomen, V. A., Varadarajan, M., Sun, C., Bell, G., Yuan, B., Muellner, M. K., Nijman, S. M., Ploegh, H. L. & Brummelkamp, T. R. Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat Biotechnol 29, 542-546, doi:10.1038/nbt.1857 (2011).